MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Interval from onset of Parkinson disease to onset of motor and non-motor complications in Leucine-rich repeat kinase 2 (LRRK2) G2019S positive versus matched PD controls

    S. Gunzler, D. Riley, A. Wilson-Delfosse, S. Chen, J. Mieyal, C. Tatsuoka (Cleveland, OH, USA)

    Objective: To compare the latency between onset of Parkinson disease (PD) symptoms and onset of motor and non-motor complications of PD, between G2019S LRRK2 mutation…
  • 2017 International Congress

    Genetic analysis of RAB39B mutations in early-onset and familial Parkinson’s Disease in a Taiwanese population.

    C.-H. Lin, H.-H. Lin, R.-M. Wu, H.-I. Lin (Taipei, Taiwan)

    Objective: To examine the genetic contribution of RAB39B to early-onset and familial PD in a Taiwanese population. Background: Loss of function mutations in RAB39B were…
  • 2017 International Congress

    Genetic and pharmacological rescue of DJ-1 loss-of-function caused by a c.192G>C mutation in PARK7

    I. Boussaad, C. Obermaier, Z. Hanss, N. Weisschuh, B. Schmid, S. Hoffmann, L. Burbulla, C. Klein, S. Duga, D. Krainc, T.G. Gasser, B. Wissinger, R. Krüger (Esch-sur-Alzette, Luxembourg)

    Objective: In this study we investigate the cellular mechanism underlying the Parkinson’s disease (PD)-associated mutation c.192G>C in PARK7 and present a compound treatment that rescues…
  • 2017 International Congress

    First Reported Case of Parkinsonism in a Patient with Argininosuccinate Lyase Deficiency

    K. Woodward, D. Bhatti, E. Rush (Omaha, NE, USA)

    Objective: The purpose of this case report is to detail the phenotype of parkinsonism encountered in a patient with Argininosuccinate Lyase Deficiency (ASLD) that has…
  • 2017 International Congress

    Absence of depression in de novo Parkinson’s disease: a benign motor phenotype?

    H.S. YOO, Y. Lee, J.J. Lee, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Republic of Korea)

    Objective: This study aimed to assess the impact of early depression on motor deficits relative to the level of striatal dopaminergic depletion in patients with…
  • 2017 International Congress

    Serum uric acid levels and freezing of gait in Parkinson’s disease

    R. Ou, B. Cao, Q. Wei, Y. Hou, Y. Xu, W. Song, B. Zhao (Chengdu, China)

    Objective: To investigate the relationship between serum Uric acid (UA) levels and freezing of gait (FOG) in Parkinson’s disease (PD). Background: UA is a natural…
  • 2017 International Congress

    Leg Stereotypy Disorder: Clinical Characteristics and Prevalence

    J. Jankovic, M. Lotia, M. York, A. Strutt (Houston, TX, USA)

    Objective: To describe phenomenology and prevalence of leg stereotypy disorder (LSD) Background: LSD is characterized chiefly by repetitive, rhythmical, stereotyped leg movement when sitting (Jankovic…
  • 2017 International Congress

    Item Response Theory Analysis of the MDS-UPDRS Items

    G. Stebbins, C. Goetz, Y. Liu, S. Luo (Chicago, IL, USA)

    Objective: To investigate the measurement characteristics of the MDS-UPDRS using item response theory (IRT) approaches. Background: The MDS-UPDRS has become the most frequently used assessment…
  • 2017 International Congress

    Genotype-Phenotype correlations and expansion of the molecular spectrum of AP4M1-related Hereditary Spastic Paraplegia

    S. Efthymiou, C. Bettencourt, V. Salpietro Damiano, H. Houlden (London, United Kingdom)

    Objective: To identify possible novel variants in a HSP family from Greece.  Background: Autosomal recessive hereditary spastic paraplegia (HSP) due to AP4M1 mutations is a…
  • 2017 International Congress

    Efficacy and safety of incobotulinumtoxinA (inco/A) for essential tremor using kinematics-guided clinical decision support: A randomized, double-blind, placebo-controlled trial

    M. Jog, J. Lee, M. Althaus, A. Scheschonka, H. Dersch, E.T. Study Team, D. Simpson (London, ON, Canada)

    Objective: To demonstrate improvement of arm tremor severity and hand function with kinematics-guided inco/A therapy Background: Botulinum neurotoxin A (BoNT-A) therapy of debilitating tremor symptoms…
  • « Previous Page
  • 1
  • …
  • 131
  • 132
  • 133
  • 134
  • 135
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • #25179 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley